Form 8-K - Current report:
SEC Accession No. 0001641172-25-010526
Filing Date
2025-05-15
Accepted
2025-05-15 08:05:12
Documents
15
Period of Report
2025-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38084
2 EX-99.1 ex99-1.htm EX-99.1 52712
3 GRAPHIC ex99-1_001.jpg GRAPHIC 25440
  Complete submission text file 0001641172-25-010526.txt   305157

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE evfm-20250515.xsd EX-101.SCH 3009
5 XBRL LABEL FILE evfm-20250515_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE evfm-20250515_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 25948826
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)